J&J's Weldon Challenges Use Of Evidence-Based Medicine For Policy Decisions
This article was originally published in The Pink Sheet Daily
Executive Summary
Cost "really has no place in a discussion about quality," outgoing chair Weldon tells the Pharmaceutical Research & Manufacturers of America annual meeting.
You may also be interested in...
PhRMA’s Unlucky Class Of ‘06
Dolan's removal from Bristol creates succession challenge for the trade association as well.
PhRMA’s Unlucky Class Of ‘06
Dolan's removal from Bristol creates succession challenge for the trade association as well.
Bristol/Sanofi’s Plavix Settlement Denied Antitrust Clearance
States attorneys general reject a proposed settlement one day after the companies announced they are facing a related DoJ criminal investigation.